STOCK TITAN

Fulcrum Therapeutics (FULC) Revenue by Year

FULC NASDAQ

Fulcrum Therapeutics, Inc. generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior fiscal year. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Fulcrum Therapeutics, Inc. has filed alongside them.

FY2025 annual
Revenue $0
YoY -100.0%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

FULC Revenue by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY25S-4FY24S-4FY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-K
Revenue$0-100.0%$80.0M+2752.0%$2.8M-55.8%$6.3M-66.9%$19.2M+117.2%$8.8MN/AN/A

FULC Revenue by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4Q3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4Q3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
RevenueN/AN/AN/AN/A$0n/m$0-100.0%N/A$0-100.0%$0-100.0%$80.0M+8990.9%$0-100.0%$871K+27.2%

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Fulcrum Therapeutics, Inc. financials

Frequently Asked Questions

Fulcrum Therapeutics, Inc. generated $0 in revenue in fiscal year 2025.

Fulcrum Therapeutics, Inc. (FULC) revenue fell by 100.0% year over year, from $80.0M to $0 in fiscal year 2025.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Fulcrum Therapeutics, Inc. (FULC) reported on that line in every period on record.